At least three COVID-19 vaccine doses before SARS-CoV-2 infection were associated with less and better for two years.
Evidence
An observational serial survey cohort of 4809 PCR-tested people in Northern Israel included 1377 reporting infection and linked three pre-infection doses to lower long-COVID symptom reporting (aOR 0.66) and higher QoL.
Caveat
Vaccination timing was not randomized, outcomes were survey-reported, and durability across reinfection and emerging variants was not tested.
Simplified
BACKGROUND: The long-term impact of COVID-19 vaccination on post-acute COVID-19 symptoms and associated (QoL) changes remains incompletely described. This study aimed to explore the impact of the timing of COVID-19 priming and booster doses, on reporting symptoms and associated QoL changes.
METHODS: Individuals who had PCR testing for SARS-CoV-2 processed in government hospitals in Northern Israel between 15March 2021 and 15June 2022 were invited to answer serial online surveys collecting information on SARS-CoV-2 infection, vaccination status and post-acute symptoms every 3-4 months for two years. Participants were categorized into groups based on the number of doses received prior to infection. We compared these groups over time in terms of reporting post-COVID symptom clusters and QoL, using population-average and mixed-effects regression models, respectively. th th
RESULTS: A total of 4809 individuals are enrolled and respond to up to five follow-up surveys. Of these, 1377 (28.61%) report a positive SARS-CoV-2 test, while 3432 (71.39%) report a negative result. After adjustment for potential confounders, receiving at least three COVID-19 vaccine doses prior to infection is associated with a 34% reduction in the likelihood of reporting at least one long COVID symptom cluster compared to being unvaccinated (adjusted odds ratio [aOR] = 0.66, p = 0.022). Pre-infection vaccination is also associated with higher quality of life (QoL) scores (β = 0.07, p < 0.001). The estimated vaccine effectiveness of three pre-infection doses against long COVID over a two-year period is 26.5% (95% CI: 10.8-39.4). This protective effect remains stable over time. In contrast, vaccination received after infection shows no association with long COVID symptoms or QoL outcomes.
CONCLUSIONS: Receiving at least three COVID-19 vaccine doses prior to SARS-CoV-2 infection provides a sustained protective effect against long COVID and its negative impact on quality of life for at least two years. The longer-term durability of this protection, the role of reinfection, and the influence of emerging viral variants remains to be investigated.
Key numbers
34%
Reduction in symptoms
Likelihood of reporting at least one symptom cluster
26.5%
Vaccine effectiveness against
Estimated over a two-year period for three pre-infection doses
0.86
score for vaccinated individuals
score for those infected and vaccinated with three doses
Full Text
We can’t show the full text here under this license.
Long Covid
mRNA Technology